Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 24

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 24
---
, responses to business opportunities, and general and administrative expenses. 

We are actively exploring additional sources of liquidity and may seek to raise such capital through, among other means, public or private equity offerings (including sales of our common stock under our at-the-market equity offering program), debt financings, corporate collaborations and/or licensing arrangements. However, general market conditions or the market price of our common stock may not support these capital raising transactions on terms favorable to us, or at all. If we are unable to obtain adequate financing or financings on terms satisfactory to us when we require it, we will be forced to undertake capital preservation measures that may include delaying or reducing our product development programs and commercialization efforts, materially curtailing or eliminating our operations, selling or disposing of our rights or assets, pursuing a sale or other strategic transactions, or undergoing restructuring or insolvency proceedings. Factors that could limit our ability to raise additional capital after this offering include, among other matters:

 ·the expectation that we will continue to incur losses and generate negative cash flows from operations;    ·our substantially limited liquidity and capital resources to meet our obligations as they become due;    ·the potential that our common stock will be delisted by Nasdaq in the event we fail to maintain compliance with the minimum bid price requirement; and    ·risks and uncertainties that are described in more detail in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections in this Annual Report on Form 10-K.

 19Table of Contents

To date, we have financed our operations through the net proceeds from offerings of common and preferred stock, warrants and convertible notes. Our future funding requirements will depend on many factors, including, but not limited to:

 ·the costs, timing and outcomes of regulatory reviews associated with our future products, including TAEUS applications;    ·the progress, timing, costs and outcomes of our clinical studies, including the ability to timely enroll patients in such clinical trials;    ·the costs and expenses of expanding our sales and marketing infrastructure;    ·the costs and timing of developing variations of our TAEUS applications and, if necessary, obtaining regulatory clearance of such variations;    ·the degree of success we experience in commercializing our products, particularly our TAEUS applications;    ·the extent to which our TAEUS applications are adopted by hospitals for use by primary care physicians, hepatologists, radiologists and oncologists for diagnosis of fatty liver disease and the thermal ablation of lesions